S8139

Sulindac

≥98.0%

• Synonyme(s) : (Z)-5-Fluoro-2-methyl-1-[p-(methylsulfinyl)benzylidene]indene-3-acetic acid
• Formule empirique (notation de Hill) : C₂₀H₁₇FO₃S
• CAS Number: 38194-50-2
• Poids moléculaire : 356.41
• Numéro CE : 253-819-2
• Numéro MDL: MFCD00599589
• Code UNSPSC : 12161501
• ID de substance PubChem : 57654635
• Nomenclature NACRES : NA.77

Propriétés

• Source biologique: synthetic (organic)
• Niveau de qualité: 200
• Essai: ≥98.0%
• Forme: powder
• Technique(s): HPLC: suitable; gas chromatography (GC): suitable
• Solubilité: methanol: 50 mg/mL
• Application(s): forensics and toxicology; veterinary
• Auteur: Merck & Co., Inc., Kenilworth, NJ, U.S.
• Chaîne SMILES: CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C/c3ccc(cc3)S(C)=O
• InChI: 1S/C20H17FO3S/c1-12-17(9-13-3-6-15(7-4-13)25(2)24)16-8-5-14(21)10-19(16)18(12)11-20(22)23/h3-10H,11H2,1-2H3,(H,22,23)/b17-9-
• Clé InChI: MLKXDPUZXIRXEP-MFOYZWKCSA-N
• Informations sur le gène: human ... ALB(213), PTGS1(5742), PTGS2(5743)

Description

Application

Treatment of human colorectal cancer cell lines induces MRP1 and MRP3 but not other members of the MRP family. Reported to significantly increase the cytotoxicity of the anthracyclines (doxorubicin, daunorubicin and epirubicin), as well as teniposide, VP-16 and vincristine. Sulindac was tested for its effect on heat-induced denaturation of albumin in vitro²⁸ and its ability to bind to human plasma protein.²⁹

Actions biochimiques/physiologiques

Nonsteroidal anti-inflammatory; preferential inhibitor of COX-1.

Sulindac is non-steroidal anti-inflammatory drug and an analgesic that has antiproliferative and apoptotic effects. It inhibits the expression and activity of cyclooxygenase-2 in human colon cancer cells^25,26 and reduces tumor burden in adenomatous polyposis patients.²⁷

Caractéristiques et avantages

This compound is a featured product for ADME Tox research. Click here to discover more featured ADME Tox products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Informations sur la sécurité

• Pictogrammes: GHS06,GHS08
• Mention d'avertissement: Danger
• Mentions de danger: H301,H317,H334,H361
• Conseils de prudence: P201 - P280 - P301 + P310 + P330 - P302 + P352
• Classification des risques: Acute Tox. 3 Oral - Repr. 2 - Resp. Sens. 1 - Skin Sens. 1
• Code de la classe de stockage: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• Classe de danger pour l'eau (WGK): WGK 3
• Point d'éclair (°F): Not applicable
• Point d'éclair (°C): Not applicable
• Équipement de protection individuelle: Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges